Orthocell Limited announced the appointment of Ravi I. Thadhani, MD, MPH, as independent Non-Executive Director. With more than 30 years as a general and specialized physician, researcher, medical administrator and commercialization adviser, Dr. Thadhani has extensive experience in patient care, advancing novel research programs, US regulatory pathways and commercialization of devices and therapeutics. Highlights from Dr. Thadhani's career: Served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors providing expert guidance to the FDA and companies regarding the regulatory requirements for approval of medical devices and therapeutics; High-profile healthcare administration roles, most recently professor of medicine at Harvard Medical School and chief academic officer and dean for faculty affairs for Mass General Brigham hospital, where he oversaw a $2.3 billion research enterprise; Expert advisor to multiple global pharmaceutical companies including Sandoz, Shire, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring Secured significant research funding from global US Healthcare companies including Amgen, Abbott, Serono, Kaneka, and Genzyme Co-author of more than 300 scientific publications, including articles in top medical journals,
such as the New England Journal of Medicine, the Lancet and the Journal of the American Medical Association. Recipient of several national awards, and has extensive track record of recruiting and mentoring women and under-represented minorities. Dr. Thadhani was appointed on January 2023 as the executive vice president for health affairs of Emory University, executive director of Emory's Woodruff Health Sciences Center, and vice chair of
the Emory Healthcare Board of Directors.